Just over 40 days after Canada’s official cannabis legalization date on October 17, 2018, consumers will be treated to deals and exciting new products online with the industry’s first official Cyber Monday.

Set for November 26, 2018, this year’s Cyber Monday will feature for the very first time, the ability to purchase cannabinoid products (those that include THC and/or CBD). The addition of these new products could likely push Cyber Monday numbers up to another new record, following last year’s incredible $6.6 billion in online sales in just one day.

Merchants of cannabinoid products are set to benefit from the burst of online shoppers on Cyber Monday, including Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF), Aurora Cannabis Inc. (TSX: ACB) (OTC: ACBFF), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aphria Inc. (TSXV: APH) (OTC: APHQF), and Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF).

NEW CANNABINOID CYBER OFFERINGS

The legality of online cannabis related purchases has already been discussed in different jurisdictions within Canada. In Alberta, online pot shopping will be legal, but will require double ID check. In Ontario, the province has side-stepped the concept of government-run brick and mortar stores, leaving private retailers out in the public marketplace, but the online sales will be governmental.

However, with CBD products, there are several US states that are also open for business for customers looking to purchase wares. According to Business Insider, CBD oil has already turned into a $1 billion business.

Which is what vertically-integrated Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) has prepared itself for, in the lead up to the 2018 Cyber Monday. Through its wholly-owned subsidiary, Vergence Naturals Ltd., Abattis is preparing to launch a new product line—the first set of twelve products the company hopes to launch over a 36-month period.

“We are very proud to have developed products that safely reduce pain and modulate inflammation. Searches for pain remedies are among the top cannabis-related searches on Amazon and Google and we are confident that our products will be well received by the growing number of consumers interested in cannabinoid-based therapies for pain and inflammation,” said Dr. Brazos Minshew MSc, ND, President of the Abattis Medical Advisory Board in the corresponding press release.

From the beginning of the company’s story, Abattis has built itself to be fully vertically-integrated—always with an eye on the potential of generating a large portion of its revenues through its Vergence Naturals product line. As a whole, the Abattis structure includes not only Vergence, but also lab services through its subsidiary XLABS Therapeutics that can produce high purity oils and isolates for the market, the highly-successful Green Tree Therapeutics vaporizers line, and a majority stake in CannaNUMUS Blockchain, which proposes a compelling solution to help the industry reduce administrative overhead, costs, and trading friction.

While Abattis is now fully prepared to shift gears towards focusing on its revenue generating assets, especially in Canada—the company’s structure is ultimately built for the possibility of future global expansion as well.

Much of the preparation towards the Cyber Monday launch has been towards unique product formulation. Now that the market is clamoring for cannabinoid-infused wares, including CBD products and supplements, Abattis through its brain trust is positioning itself to be a leader in new products to help treat all types of ailments.

“Developing an effective formula was only the beginning, however. We have also secured a consistent supply of the ingredients on which our products will be based, including the rare phytocannabinoid, Alpinia Galangal,” added Dr. Minshew.

Commonly found in Indonesia and Malaysia Alpinia Galangal has historically been used to relieve gastric distress. Now more recently, the ingredient has effectively been used to improve mental alertness and attention and has also been combined with cisplatin to treat lung cancer. More relevant to Abattis’s applications, Alpinia Galangal also binds to and activates both CB1 and CB2, the body’s main cannabinoid receptors—By activating these receptors, Alpinia Galangal reduces pain and inflammation and improves mobility.

More locally, Abattis recently announced the impending construction of a large-scale growing facility on Gabriola Island. The state-of-the-art facility will include growing, extraction, propagation areas, and a genetics lab.

Through establishing itself in multiple levels of the cannabis sector, Abattis is following in the steps that larger players such as Canopy Growth, Aurora Cannabis, and Aphria did en route to their current positions. Canada’s soon-to-be-legal and favorable cannabis environment is nearly perfect in the lead up to Cyber Monday.

ADDITIONAL CANNABIS CYBER WARES

Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF)

Still the largest player in the cannabis space, Canopy Growth’s product line is wide. The Canopy family includes its popular Tweed brand of dried cannabis flower products, to its international medical brand Spectrum Cannabis, award-winning DNA Genetics line, celebrity-endorsed Leafs by Snoop line, the Craftgrow Collection, and FORIA US-based cannabis oil products. Many of Canopy’s online sales come through its Spectrum Cannabis online store.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON)

The multi-billion-dollar Cronos Group boasts three main brand assets: Peace Naturals Medicinal Cannabis, Original BC (OGBC), and a minority stake in Whistler Medical Marijuana Company (WMMC). Peace Naturals markets not only dried flower products, but also a variety of cannabis oils with differing blends of both THC and CBD, all of which are available for purchase online. To-date, Cronos’s OGBC product line is still in development, as the company’s website at press time still has a COMING SOON announcement on its brands.

Aurora Cannabis Inc. (TSX: ACB) (OTC: ACBFF)

Unlike Canopy and Cronos, Aurora Cannabis’ main brand is its own moniker of “Aurora”. Through the company’s website, consumers can purchase a wide variety of products, including dried cannabis, cannabis oils, milled decarb (powder), and milled blends. Customers can easily filter their selections based on THC and CBD, as well as the type of plant—ie. Indicas, Sativas, and Hybrids. The company also seeks to facilitate online buying easier for its customers through a mobile app designed for enhanced buying convenience.

Aphria Inc. (TSXV: APH) (OTC: APHQF)

Much like its Alberta counterparts at Aurora, Ontario-based Aphria Inc. brands all of its products solely as “Aphria”. The company also has several online offerings of products, including dried cannabis products spanning Sativa, Indica, and Hybrid genetics, as well as a series of THC and CBD focused cannabis oils. Customers are encouraged to register as patients in order to access the company’s online store. However, it should be expected that once Canadian lawmakers give the official greenlight, all Canadian adults will have access Aphria products, both with or without a doctor’s referral.

Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF)

Abattis was built out from its inception to be a complete full-service, vertically integrated competitor in the cannabis space, specializing not only in cultivation, but in extraction, testing, and marketing of new products and brands. Through its Vergence Naturals product line, the company has announced that new products will officially be launched on November 26, 2018—Cyber Monday.

Disclaimer

Nothing in this article should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this article is not provided to any individual with a view toward their individual circumstances. Baystreet.ca has been paid a fee of forty six thousand dollars in shares for Abattis Bioceuticals Corp. advertising by the company. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article as the basis for any investment decision. The owner/operator of Baystreet.ca owns shares of Abattis Bioceuticals Corp. and have no plans of selling any shares in the next 72 hours from this publication date, but reserve the right to buy and sell shares of Abattis Bioceuticals Corp. at any time thereafter without any further notice. Baystreet.ca may participate in private placements with the company for common stock in the company, no further notice will be given. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.